Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of L04TD2 and L04RD1 (Telmisartan/Dapagliflozin) in Healthy Volunteers
NCT05581693Phase 1Completed
- Sponsor
- Celltrion
- Start
- Sep 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan and dapagliflozin in hypertension (HTN) (2 arms), sponsored by Celltrion. Primary endpoints: Area under the plasma concentration-time curve from time 0 to time t at 48 hours and Maximum plasma concentration at 48 hours. Started Sep 2022; status: completed.
02
Drugs
telmisartandapagliflozin
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05581693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05581693.